Signet-ring cell carcinoma of the breast: a case report

Table 1 Summary of antibodies used in the assessment of the lesion

Antibody	Company	Clone	Dilution
ER	Ventana	SP1	1:50
PR	Ventana	IE2	1:150
GCDFP-15	Dako	23A3	1:50
Mammaglobin	Zeta Corporation	304-1A5	1:120
MUC1	Cell Marque	Ma695	1:120
MUC2	Zeta Corporation	Ccp58	1:120
CK7	Invitrogen	OV-TL12/30	1:150
CK20	Epitomics	EP23	1:150
CDX2	Epitomics	EP25	1:200
E-ca	Epitomics	EP6	1:150
Hep Par 1	Zeta Corporation	OCH1E5	1:150
TTF-1	LeicaMicrosystems	SPT24	1:180

Cell Marque, Rocklin, CA, USA; Dako, Carpinteria, CA, USA; Epitomics, Burlingame, CA, USA; Invitrogen, Carlsbad, CA, USA; Leica Microsystems,Wetzlar, Germany; Ventana, Oro Valley, AZ, USA; Zeta Corporation, Sierra Madre, CA, USA.CDX2, caudal type homeobox 2; CK7, cytokeratin 7; CK20, cytokeratin 20; E-ca, E-cadherin; ER, estrogen receptor; GCDFP-15, gross cystic disease fluid protein-15; Hep Par1, hepatocyte paraffin 1; MUC1, mucin 1 glycoprotein; MUC2, mucin 2 glycoprotein; PR, progesterone receptor; TTF-1, thyroid transcription factor-1.

ISSN: 1477-7819